Article Sidebar

PDF (Tiếng Việt)
Published: 2024-11-11
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v183i10.2750
Issue
Vol. 183 No. 10 (2024)
Section
Các bài báo
How to Cite
Huyền, T. T., Vinh, N. T. H., Phương, P. T. M., Thùy N. T. T., Giang, Q. T. H., My, L. H., & Doanh, L. H. (2024). Serological diagnosis of Mycoplasma pneumoniae in patients with erythema multiform, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Journal of Medical Research, 183(10), 80-89. https://doi.org/10.52852/tcncyh.v183i10.2750

Serological diagnosis of Mycoplasma pneumoniae in patients with erythema multiform, Stevens-Johnson syndrome, and toxic epidermal necrolysis

Tran Thi Huyen, Nguyen Thi Ha Vinh, Pham Thi Minh Phuong, Nguyen Thi Thanh Thuy, Quach Thi Ha Giang, Le Huyen My, Le Huu Doanh

Main Article Content

Abstract

Mycoplasma pneumoniae causes not only pulmonary disease but also mucocutaneous manifestations. This cross-sectional descriptive study was conducted on 54 patients with erythema multiform (EM), 30 patients with Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), and 30 healthy controls, aiming to determine the seropositivity rates for M. pneumoniae and to examine the association between M. pneumoniae with clinical features in these groups. The findings revealed that IgG and IgM seropositivity rates for M. pneumoniae in the SJS/TEN group were 13.33% and 33.33%, respectively; in the EM group, 20.37% and 25.93%; and in the healthy group, 10% and 16.67%. These differences were not statistically significant. In the SJS/TEN group, the IgM seropositivity rate for M. pneumoniae in individuals under 50 was 53.33%, higher than in those aged 50 or older (p < 0.05). In the EM group, the IgM seropositivity rate in patients younger than 30 was 40%, higher than in those aged 30 or older (p < 0.05). No age-related difference was observed in the healthy group. Among the EM patients, the IgM seropositivity rate for M. pneumoniae in febrile patients was 77.78%, significantly higher than the afebrile patients (15.56%, p = 0.0005). There was no significant difference between patients with and without mucosal involvement.

Article Details

Keywords

Erythema multiforme, Mycoplasma pneumoniae, Stevens-Johnson syndrome, toxic epidermal necrolysis

References

1. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993; 129(1):92-96.
2. Assier H, Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol. 1995; 131(5):539-543.
3. Vujic I, Shroff A, Grzelka M, et al. Mycoplasma pneumoniae-associated mucositis--case report and systematic review of literature. J Eur Acad Dermatol Venereol JEADV. 2015; 29(3):595-598. doi:10.1111/jdv.12392.
4. Đỗ Thị Quỳnh Nga, Trần Thị Hải Âu, Vũ Thị Kim Liên và cộng sự. Khảo sát liên quan giữa HLA-B*58:01 và nguy cơ mắc các phản ứng dị ứng nặng do điều trị allopurinol tại Bệnh viện Bạch Mai, Hà Nội. Tạp chí Y học dự phòng; 8(168):396.
5. Nguyen DV, Chu HC, Nguyen DV, et al. HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. Asia Pac Allergy. 2015;5(2):68-77. doi:10.5415/apallergy.2015.5.2.68.
6. Chung WH, Wang CW, Dao RL. Severe cutaneous adverse drug reactions. J Dermatol. 2016; 43(7): 758-766. doi:10.1111/1346-8138.13430.
7. Su JR, Haber P, Ng CS, et al. Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999-2017. Vaccine. 2020; 38(7): 1746-1752. doi:10.1016/j.vaccine.2019.12.028.
8. Sah R, Neupane S, Khadka S, et al. A Case Study of Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis (SJS-TEN) Overlap in Mycoplasma pneumoniae-Associated Tracheobronchitis. Case Rep Infect Dis. 2019; 2019:5471765. doi:10.1155/2019/5471765.
9. Grieb G, Alazemi M, Das R, Dunda SE, Fuchs PC, Pallua N. A rare case of toxic epidermal necrolysis with unexpected Fever resulting from dengue virus. Case Rep Dermatol. 2010; 2(3):189-194. doi:10.1159/000322963.
10. Tagajdid MR, Doblali T, Elannaz H, Hammi S, Belfequih B, Mrani S. Reactivation of cytomegalovirus in a patient with stevens-johnson syndrome-toxic epidermal necrolysis. Iran J Med Sci. 2013; 38(2 Suppl):195-197.
11. Dash S, Sirka CS, Mishra S, Viswan P. COVID-19 vaccine-induced Stevens-Johnson syndrome. Clin Exp Dermatol. 2021; 46(8):1615-1617. doi:10.1111/ced.14784.
12. Boualila L, Mrini B, Tagmouti A, et al. Sinopharm COVID-19 vaccine-induced Stevens-Johnson syndrome. J Fr Ophtalmol. 2022; 45(4): e179-e182. doi:10.1016/j.jfo.2021.12.005.
13. Muhd Besari A, Lim JA, Vellaichamy PT, Hussain FA, Kamaludin Z, Nor M. Stevens-Johnson syndrome as a primary skin manifestation of COVID-19. Postgrad Med J. Published online October 20, 2021: postgradmedj-2021-140778. doi:10.1136/postgradmedj-2021-140778.
14. Su SC, Mockenhaupt M, Wolkenstein P, et al. Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. J Invest Dermatol. 2017; 137(5): 1065-1073. doi:10.1016/j.jid.2016.11.034.
15. Ramien ML. Reactive infectious mucocutaneous eruption: Mycoplasma pneumoniae-induced rash and mucositis and other parainfectious eruptions. Clin Exp Dermatol. 2021; 46(3):420-429. doi:10.1111/ced.14404.
16. Langley A, Anooshiravani N, Kwan S, Zeller J, Pope E. Erythema Multiforme in Children and Mycoplasma pneumoniae Aetiology. J Cutan Med Surg. 2016; 20(5): 453-457. doi:10.1177/1203475416639018.